<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556839</url>
  </required_header>
  <id_info>
    <org_study_id>ENGOT-Cx10 / BEATcc</org_study_id>
    <secondary_id>2018-000367-83</secondary_id>
    <secondary_id>ENGOT-Cx10</secondary_id>
    <secondary_id>GEICO 68-C</secondary_id>
    <secondary_id>JGOG1084</secondary_id>
    <secondary_id>GOG-3030</secondary_id>
    <nct_id>NCT03556839</nct_id>
  </id_info>
  <brief_title>Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix</brief_title>
  <official_title>A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Investigación en Cáncer de Ovario</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MaNGO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NSGO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Japanese Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Español de Investigación en Cáncer de Ovario</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will integrate the efficacy of combining the anti programmed death-ligand 1
      (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent
      or recurrent carcinoma of the cervix, namely cisplatin/paclitaxel/bevacizumab. It will be
      explored the combination of bevacizumab plus atezolizumab, with no patient selection based on
      PD-L1 expression, allowing an all-comer assessment of atezolizumab activity.

      The study is a randomized open label phase III trial to investigate the impact of
      atezolizumab in combination with bevacizumab and cisplatin/paclitaxel chemotherapy on overall
      survival and will employ the intent to treat principle, and random assignment to one of the 2
      arms will be balanced according to disease histology (squamous versus adenocarcinoma), prior
      platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior
      cis-RT) and chemotherapy backbone (cisplatin versus carboplatin).

      This trial will be run in an open label design due to the following considerations: the
      control arm is the standard of care for women diagnosed with metastatic, persistant or
      recurrent cervical cancer because of its impact on overall survival and the primary endpoint
      of the study is overall survival (OS), so blinding is not needed to ensure a robust
      assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given that both Vascular Endothelial Growth Factor (VEGF) and PD-L1 appear important in
      cervical cancer pathogenesis, this study is designed to test the hypothesis that breaking of
      immune tolerance by PD-1/PD-L1 blockade will enhance the efficacy of anti-VEGF therapy in the
      treatment of patients with metastatic , persistent or recurrent cervical cancer. There are
      several data suggesting that atezolizumab and bevacizumab may be synergistic. Enhanced tumor
      angiogenesis is commonly associated with absence of tumor-infiltrating T cells in patients.
      There is evidence in ovarian cancer that tumor expression of VEGF is negatively correlated to
      the density of CD8+ TILs and this phenotype is associated with early recurrence, consistent
      with prior studies showing a correlation of VEGF to early recurrence and short survival.
      Furthermore, in ascites, high levels of VEGF correlate to low numbers of NK T-like CD3+CD56+
      cells.

      In addition to promoting tumor angiogenesis, there is increasing evidence that VEGF plays a
      role in cancer immune evasion through several different mechanisms. Indeed, emerging evidence
      suggests that the endothelium acts as a selective barrier, allowing certain T cell subsets,
      notably T regulatory (Treg) cells, to traffic more effectively into the tumor contributing to
      tumor immune tolerance. In addition, some experiments have shown that tumour hypoxia promotes
      the recruitment of regulatory T (T reg) cells through induction of expression of the
      chemokine CC-chemokine ligand 28 (CCL28), which, in turn, promotes tumour tolerance and
      angiogenesis.

      Some immunosuppressive activities of VEGF, however, can be reversed by inhibition of VEGF
      signaling. Mice exposed to pathophysiologic levels of VEGF exhibited impaired dendritic cell
      function, which could be restored by blockade of VEGFR2.

      In turn, the anti-tumor effect of angiogenesis blockade requires CD8+ T cells supporting the
      notion that VEGF-A do not simply promote tumor growth through angiogenesis. Thus, peripheral
      immune tolerance and angiogenesis programs seem closely connected and cooperating to sustain
      tumour growth.

      In addition, there is evidence that anti-VEGF therapy and immunotherapy act synergistically.
      Motz et al have suggested that the combination of anti-VEGF-A antibody and immunotherapy with
      adoptive T cell transfer led to a superior infiltration of tumor-reactive T cells than any
      single approach. Indeed, in a murine melanoma model, VEGF blockade synergized with adoptive
      immunotherapy, as evidenced by improved anti-tumor activity, prolonged survival, and
      increased trafficking of T cells into tumors. These data are reminiscent of the additive
      benefit observed in patients by combining recombinant interferon-alpha therapy and
      bevacizumab, a recombinant, humanized therapeutic antibody directed against VEGF, for the
      treatment of metastatic renal cell carcinoma.

      More evidence has come from a clinical study of subjects with melanoma combining the
      checkpoint inhibitor (anti-CTLA-4) ipilimumab and bevacizumab. In 46 patients, the combined
      therapy yielded a 19.6% objective response rate, stable disease in 13%. All responses were
      durable &gt;6 months and median survival was 25.1 months, much prolonged compared to
      ipilimumab's expectation in metastatic melanoma. Activated vessel endothelium with extensive
      CD8+ T cell and macrophage cell infiltration was observed in post-treatment biopsies, as well
      as marked increases in CD4/CCR7/CD45ROm central memory cells in peripheral blood in the
      majority of patients.

      Thus, an emerging paradigm supported by the data above is that angiogenesis and immune
      suppression are two facets of a linked biological program. Tumors seem to co-opt these
      existing mechanisms that are normally required to limit excessive inflammation and promote
      tissue recovery during infection or wound healing. The execution of this program sustains
      tumor growth and promotes immunologic tolerance. Because of the intimate relationship between
      angiogenesis and immunosuppression, it is thus expected that inhibiting both pathways will
      result in improved and more durable clinical benefit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>48 months</time_frame>
    <description>Time from the date of randomization to the date of death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>48 months</time_frame>
    <description>Time from the date of randomization to the date of first documentation of disease progression or death due to any cause, whichever occurs first based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>48 months</time_frame>
    <description>Based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>48 months</time_frame>
    <description>Based on investigator assessment using the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events of combining atezolizumab to chemotherapy plus bevacizumab compared to cisplatin/paclitaxel (CP) plus bevacizumab.</measure>
    <time_frame>48 months</time_frame>
    <description>Incidence, nature and severity of adverse events (AEs) assessed by CTCAE version 4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First subsequent therapy</measure>
    <time_frame>48 months</time_frame>
    <description>Time from randomization to first subsequent therapy or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival 2</measure>
    <time_frame>48 months</time_frame>
    <description>Time from randomization to the second event of disease progression per radiological criteria, start of a new line of therapy, due to symptomatic deterioration or to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported outcomes (PROs) of function and health related quality of life (HR-QOL) associated with atezolizumab + CP + bevacizumab compared to bevacizumab + CP alone, as measured by the functional and GHS/ HRQoL scales of EORTC QLQ-C30</measure>
    <time_frame>48 months</time_frame>
    <description>Mean and mean changes from baseline score in patient function (role, physical) and GHS/HRQoL, by assessment timepoint and between treatment arms, as assessed by the functional and GHS/HRQoL scales of EORTC QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of atezolizumab</measure>
    <time_frame>36 months</time_frame>
    <description>Serum concentration (Cmin) of atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of atezolizumab</measure>
    <time_frame>36 months</time_frame>
    <description>Serum concentration (Cmax) of atezolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-therapeutic antibodies (ATAs)</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of ATAs during the study relative to the prevalence of ATAs at baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">404</enrollment>
  <condition>Carcinoma of the Cervix, Stage IVB</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cisplatin 50mg/m2 + paclitaxel 175mg/m2+ bevacizumab 15mg/kg i.v D1 Q3W. Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologic therapy, namely bevacizumab, upon investigator discussion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cisplatin 50mg/m2 + paclitaxel 175mg/m2 + bevacizumab 15mg/kg + atezolizumab 1200mg i.v, D1 Q3W.Patients who achieve a complete response after ≥6 treatment cycles may be allowed to continue only on biologics therapy, namely bevacizumab plus atezolizumab, upon investigator discussion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female patients must be ≥18 years of age.

          2. Signed informed consent before any study-specific procedure

          3. Able (in the investigator´s judgment) to comply with the study protocol

          4. GOG/Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          5. Life expectancy ≥3 months

          6. Histologically- or cytologically-confirmed diagnosis of metastatic (stage IVB),
             persistent, or recurrent cervical cancer (histologies other than squamous cell,
             adenocarcinoma, or adenosquamous will be excluded) not amenable for curative treatment
             with surgery and/or radiation therapy. The inclusion of patients with adenocarcinoma
             histology will be capped to 20% of the whole study population.

          7. No prior systemic anti-cancer therapy for metastatic or recurrent disease.

          8. Measureable disease by RECIST v1.1 criteria.

          9. A tumor specimen is mandatory at study entry.

         10. Adequate organ function:

             Hemoglobin ≥9 g/dL ANC ≥1.5 × 109/L Lymphocyte count ≥0.5 × 109/L Platelet count ≥100
             x 109/L

         11. Adequate liver function:

             Serum albumin ≥2.5 g/dL Total serum bilirubin ≤1.5 ×ULN AST and ALT ≤2.5 × upper limit
             normal (ULN) or ≤5 × ULN if tumor involvement (liver) is present

         12. Adequate renal function:

             Patients with serum creatinine &lt;1.5 × ULN Urine dipstick for proteinuria &lt;2+.

         13. Adequate coagulation:

             Blood coagulation parameters (PTT, PT/INR): PT such that international normalized
             ratio (INR) is ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on
             a stable dose of therapeutic warfarin for management of venous thrombosis including
             pulmonary thromboembolus) and a PTT &lt;1.5 × ULN.

         14. Negative Test Results for Hepatitis:

             Negative hepatitis B surface antigen (HBsAg) test at screening Negative total
             hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test
             followed by a negative hepatitis B virus (HBV) DNA test at screening.The HBV DNA test
             will be performed only for patients who have a positive total HBcAb test.

             Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody
             test followed by a negative HCV RNA test at screening.The HCV RNA test will be
             performed only for patients who have a positive HCV antibody test.

         15. Toxicities related to previous treatments must be recovered to &lt; grade 2 (with the
             exception of alopecia).

         16. Female participants must be postmenopausal (≥ 12 months of non-therapy-induced
             amenorrhoea) or surgically sterile (absence of ovaries and/or uterus, or who received
             therapeutic radiation to the pelvis) or otherwise have a negative serum pregnancy test
             within 7 days of the first study treatment and agree to abstain from heterosexual
             intercourse or use single or combined contraceptive methods that result in a failure
             rate of &lt;1% per year during the whole treatment period of the study and for at least 5
             months (if the last study dose contained atezolizumab) or 6 months (if the last study
             dose contained bevacizumab) after the last dose of study treatment.

               -  Abstinence is acceptable only if it is in line with the preferred and usual
                  lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation,
                  symptothermal or postovulation methods) and withdrawal are not acceptable methods
                  of contraception

        Exclusion Criteria:

          1. Disease that is suitable for local therapy administered with curative intent

          2. Prior radiotherapy delivered using cobalt (rather than a linear accelerator)

          3. Patients with Stage IVA not amendable to concurrent chemo-radiation as primary
             treatment will not be eligible.

          4. Ongoing disease involving the bladder or rectum at screening/baseline

          5. Evidence of abdominal free air

          6. Bilateral hydronephrosis, unless it can be alleviated by ureteral stent(s) or
             percutaneous drainage

          7. Patients previously treated with chemotherapy except when used concurrently with
             radiation therapy. Patients who have received either concurrent paclitaxel with
             radiation therapy or carboplatin/paclitaxel as adjuvant therapy are ineligible for the
             study.

          8. Prior treatment with any anti-VEGF drug, including bevacizumab, CD137 agonists or
             immune checkpoint blockade therapies, anti-PD1, or anti-PDL1 therapeutic antibodies or
             anti-CTLA 4.

          9. Patients with a concomitant malignancy other than non-melanoma skin cancer. Patients
             with a prior invasive malignancy (except non-melanoma skin cancer ) who have had any
             evidence of disease within the last 5 years or whose prior malignancy treatment
             contraindicates the current protocol therapy.

         10. Known brain metastases or spinal cord compression. It is mandatory to perform a scan
             of the brain in cases of suspected brain metastases (CT or MRI) or spinal cord
             compression (MRI).

         11. History or evidence, following a neurological examination, of central nervous system
             (CNS) disorders, unless properly treated with standard medical treatment,(e.g.
             uncontrolled epileptic seizures). History of cerebrovascular accident (CVA, stroke),
             transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the
             first date of treatment on this study.

         12. Patients with serious non-healing wound, ulcer, or bone fracture.

         13. Acute intestinal obstruction or sub-occlusion episode in the last 6 months.

         14. Active GI bleeding or GI ulcer

         15. History of Crohn's disease or inflammatory bowel disease

         16. Prior bowel resection ≤6 weeks preceding first study dose

         17. History of diverticulitis requiring medical intervention

         18. NCI CTCAE (version 5.0) grade ≥2 enteritis

         19. Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to Day 1, Cycle 1.

         20. Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to Day 1, Cycle 1.

         21. Patients with active bleeding or pathologic conditions that carry high risk of
             bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major
             vessels.

         22. Current or recent (within 10 days before the first dose of study drug) chronic daily
             treatment with aspirin (&gt;325 mg/day), clopidogrel (&gt;75 mg/day), or current or recent
             (within 10 days before first dose of bevacizumab) use of therapeutic oral or
             parenteral anticoagulants or thrombolytic agents for therapeutic purposes.

         23. Patients with pre-existing Grade 2 or greater peripheral neuropathy.

         24. History of any grade ≥3 venous thromboembolic event (VTE)

         25. Patients with clinically significant cardiovascular disease.

         26. Uncontrolled tumor-related pain

         27. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures (once monthly or more frequently). Patients with indwelling
             catheters (e.g., PleurX) are allowed.

         28. Uncontrolled hypercalcemia (&gt;1.5 mmol/L ionized calcium or calcium &gt;12 mg/dL or
             corrected serum calcium &gt; ULN) or symptomatic hypercalcemia requiring continued use of
             bisphosphonate therapy or denosumab.

         29. History of autoimmune disease, including but not limited to myasthenia gravis,
             myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis,
             inflammatory bowel disease, vascular thrombosis associated with antiphospholipid
             syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome,
             multiple sclerosis, vasculitis, or glomerulonephritis.

             History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis
             obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active
             pneumonitis on screening chest CT scan

         30. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.

         31. Active tuberculosis

         32. Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to
             hospitalization for complications of infection, bacteremia, or severe pneumonia

         33. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1

         34. Received therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1

         35. Known human immunodeficiency virus (HIV)

         36. Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study
             Influenza vaccination should be given during influenza season only

         37. Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complications

         38. Treatment with systemic immunostimulatory agents (including but not limited to IFNs,
             IL-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle
             1, Day 1

         39. Treatment with systemic immunosuppressive medications (including but not limited to
             prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor
             necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1 The use of
             corticosteroids is allowed as premedication for paclitaxel-based regimen. All patients
             should be premedicated prior to receiving chemotherapy (including with
             corticosteroids) according to the prescription information of paclitaxel and cisplatin
             and the institutional standard of care guidance.

         40. Currently participating or has participated in a study of an investigational agent and
             received study therapy or used an investigational device within 4 weeks prior to the
             first dose of study treatment.

         41. Prior anti-cancer monoclonal antibody (mAb), prior chemotherapy, targeted small
             molecule therapy as first line treatment for the treatment of metastatic or recurrent
             cervical cancer.

         42. Women that are breastfeeding or pregnant

         43. Known hypersensitivity to bevacizumab, atezolizumab or any of theirs excipients
             (including Cremophor)

         44. Demonstration of any other neurological or metabolic dysfunction, found upon physical
             examination or laboratory tests involving a reasonable suspicion of the existence of a
             disease or condition that contraindicates the use of an experimental drug, or that
             involves an increased risk to the patient of treatment-related complications

         45. No medical or psychiatric illness that may impede the performance of a systemic or
             surgical treatment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female patients</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Oaknin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vall d´Hebron University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Javier Sanchez López, MBA MSc</last_name>
    <phone>+34 669 528 261</phone>
    <email>jsanchez@grupogeico.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carmen Marqués, MD</last_name>
    <email>cmarques@grupogeico.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mansoor Raza Mirza, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mansoor Raza Mirza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gitte-Bettina Nyvang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gitte-Bettina Nyvang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maarit Anttila, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maarit Anttila, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annika uranen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Annika uranen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sakari Hietanen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sakari Hietanen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sophie ABADIE-LACOURTOISIE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura MANSI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laura MANSI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne FLOQUET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne FLOQUET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florence JOLY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Florence JOLY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Isabelle RAY-COQUARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle RAY-COQUARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel FABBRO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michel FABBRO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé du Confluent S.A.S.</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alain LORTHOLARY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alain LORTHOLARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe FOLLANA, MD</last_name>
    </contact>
    <investigator>
      <last_name>Philippe FOLLANA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Diaconesses-Croix Saint-Simon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frédéric SELLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Frédéric SELLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas DELANOY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas DELANOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benoît YOU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benoît YOU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre CARIO-HPCA</name>
      <address>
        <city>Plerin</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Claire HARDY-BESSARD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne-Claire HARDY-BESSARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Centre René Gauducheau</name>
      <address>
        <city>Saint-herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dominique BERTON-RIGAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dominique BERTON-RIGAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Emmanuel KURTZ, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Emmanuel KURTZ, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Régaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence GLADIEFF, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurence GLADIEFF, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexandra LEARY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra LEARY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Del Piemonte Per L'Oncologia</name>
      <address>
        <city>Candiolo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio Valabrega, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giorgio Valabrega, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Di Ferrara</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Frassoldati, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Frassoldati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Lecce 'Vito Fazzi'</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Graziana Ronzino, MD</last_name>
    </contact>
    <investigator>
      <last_name>Graziana Ronzino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Lecco</name>
      <address>
        <city>Lecco</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Ardizzoia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Ardizzoia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irst Irccs</name>
      <address>
        <city>Meldola FC</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ugo De Giorgi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ugo De Giorgi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irccs S. Raffaele - Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgia Mangili, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giorgia Mangili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicoletta Colombo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicoletta Colombo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Alberto Lissoni, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Alberto Lissoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Di Napoli Irccs Pascale</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmela Pisano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmela Pisano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto (IOV) IRCCS</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Ornella Nicoletto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Ornella Nicoletto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angiolo Gadducci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Angiolo Gadducci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AUSL Romagna - P.O. di Ravenna, Lugo, Faenza, Rimini e Cattolica</name>
      <address>
        <city>Ravenna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Casanova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claudia Casanova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Usl - Irccs Di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Bologna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandra Bologna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A. Gemelli</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Domenica Lorusso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Domenica Lorusso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino, Presidio Sant'Anna</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dyonissios Katsaros, MD</last_name>
    </contact>
    <investigator>
      <last_name>Dyonissios Katsaros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ordine Mauriziano</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Annamaria Ferrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Annamaria Ferrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Universitaria Integrata Di Udine</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia Andreetta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Claudia Andreetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin Nishio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shin Nishio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saitama medical university international medical center</name>
      <address>
        <city>Hidaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kosei Hasegawa, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kosei Hasegawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido Cancer Center</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yukiharu Todo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yukiharu Todo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Hyōgo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shoji Nagao, MD</last_name>
    </contact>
    <investigator>
      <last_name>Shoji Nagao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital</name>
      <address>
        <city>Koto-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nobuhiro Takeshima, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nobuhiro Takeshima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niigata University Medical &amp; Dental Hospital</name>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takayuki Enomoto, MD</last_name>
    </contact>
    <investigator>
      <last_name>Takayuki Enomoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Munetaka Takekuma, MD</last_name>
    </contact>
    <investigator>
      <last_name>Munetaka Takekuma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisuke Aoki, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daisuke Aoki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Line Bjørge, MD</last_name>
    </contact>
    <investigator>
      <last_name>Line Bjørge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Lindemann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kristina Lindemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne Gry Bentzen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Gry Bentzen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intitut Català d' Oncolgia L' Hospitalet</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatriz Pardo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Beatriz Pardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda García, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yolanda García, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia- Donostia Unibertsitate Ospitalea</name>
      <address>
        <city>Donostia</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nerea Anzizar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nerea Anzizar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesús Alarcón, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jesús Alarcón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Oaknin, MD PhD</last_name>
      <phone>+34 932746085</phone>
      <email>aoaknin@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Ana Oaknin, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lydia Gaba, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lydia Gaba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jesus Rubio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maria Jesus Rubio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICO Girona</name>
      <address>
        <city>Girona</city>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pilar Barretina, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pilar Barretina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Guerra, MD</last_name>
    </contact>
    <investigator>
      <last_name>Eva Guerra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Manso Sánchez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luis Manso Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Redondo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andrés Redondo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jerónimo Martínez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jerónimo Martínez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Sáez, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enrique Sáez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosptial Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Cueva, MD</last_name>
    </contact>
    <investigator>
      <last_name>Juan Cueva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Esteban, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carmen Esteban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Romero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Romero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José A Pérez Fidalgo, MD</last_name>
    </contact>
    <investigator>
      <last_name>José A Pérez Fidalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Quiron de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Poveda</last_name>
    </contact>
    <investigator>
      <last_name>Andrés Poveda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Herrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ana Herrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lindköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Oscar Derke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Oscar Derke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susanne Malander, MD</last_name>
    </contact>
    <investigator>
      <last_name>Susanne Malander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kristina Hellmann, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kristina Hellmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanna Dahlstrand, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hanna Dahlstrand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Norway</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cervix</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Atezolizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

